PIA
BCRX icon

Piedmont Investment Advisors’s BioCryst Pharmaceuticals BCRX Stock Holding History

Piedmont Investment Advisors’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-1,710
Closed -$10K – 1161
2018
Q2 		$10K Buy
+1,710
New +$9.41K ﹤0.01% 1823

Other funds holding BCRX

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Piedmont Investment Advisors's BCRX Position: Q3 2018 in Review

Piedmont Investment Advisors sold out of BioCryst Pharmaceuticals (BCRX) in Q3 2018, closing a stake of 1,710 shares — an estimated $10K sold.

Piedmont Investment Advisors first reported a position in BCRX in Q2 2018 and held it in 1 quarter. The position peaked at $10K in Q2 2018. 116 funds tracked by Wall St. Rank hold BCRX as of Q3 2018.

  • Piedmont Investment Advisors reported no remaining BioCryst Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
  • Piedmont Investment Advisors sold 1,710 BioCryst Pharmaceuticals shares in Q3 2018, an estimated $10K.
  • Piedmont Investment Advisors first reported a position in BioCryst Pharmaceuticals in Q2 2018 and held it in 1 quarter.
  • Piedmont Investment Advisors's BioCryst Pharmaceuticals position peaked at $10K in Q2 2018.
  • 116 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q3 2018.

Based on Piedmont Investment Advisors's 13F filing for Q3 2018, filed 8 Nov 2018.